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ABSTRACT
Background:
        Cirrhosis is often associated with impaired lipid metabolism. However  
,there are only a few studies regarding lipid profile in cirrhosis that have been
undertaken in India. The aim of the study is to assess the degree of alteration of 
serum lipid profile in cirrhotic patients and also to detect its relationship with the 
complication of cirrhosis and assess the severity.
Materials asnd Methods:
       This prospective  study was conducted in 50 cirrhosis patients admitted in 
Thanjavur medical  hospital .A questionnaire of personal characteristics including 
history of alcoholism , detailed present and past history  was elicited for each 
patient. Serum lipid profile (total, low-density lipoprotein (LDL), high-density 
lipoprotein (HDL) cholesterol and triglyceride) was recorded. 
Lipid levels in our study was correlated with the complications of cirrhosis
.Statistical analysis was done using T –test.
Results:
Majority of the cases were in the 41-50 years age group. In patients with cirrhosis, 
the total serum cholesterol level was decreased. There was a significant decrease in 
serum HDL and LDL cholesterol and triglyceride levels . This low lipid level was 
scompared with various complications of cirrhosis and the data was statistically 
analysed  and it shows no correlation between complications and low lipid levels.
Conclusion:
In this study, we found that there was marked reduction of serum lipid profile 
values in patients with cirrhosis. Therefore, a search for lipid profile abnormality 
should be performed in every cirrhotic patient. There was no significant correlation 
between the serum lipid values and the incidence of complications of cirrhosis.
Key words: Cirrhosis, serum lipid profile  complication.
1 
 
1. INTRODUCTION 
 
Cirrhosis of liver is a very common disease which clinicians encounter both 
at primary and tertiary care. Cirrhosis is a degenerative condition of the liver in 
which normal hepatic tissue is replaced by anatomically abnormal structures, 
which eventually impair liver function.  
Liver cirrhosis represents the advanced stage of hepatic injury caused by 
chronic liver diseases such as hepatitis and alcoholic liver disease  and various 
other causes and may gradually progress towards end-stage liver failure even liver 
cancer.   
In the early 1920s, the cirrhotic mortality rates declined steeply in the United 
States due to the introduction of the national Prohibition act (Ban on the sale, 
production and transportation of alcohol). However, once the Prohibition was 
ended, the mortality rates increased again until the mid-70s, when people realized 
the consequences associated with alcohol abuse and started participating in AA 
(Alcoholics Anonymous) meetings.  
Reduced exposure to hepatitis infections also attributed to the declining 
cirrhotic mortality rate from the 70’s. Similar time trends were observed for 
European countries, with the exception of the United Kingdom and some Nordic 
2 
 
countries. Especially the high cirrhotic mortality rate across Scotland, where the 
overall alcohol consumption doubled over the past four decades, remains 
extremely alarming. With no effective treatment, at least not for advanced and 
irreversible stages, liver cirrhosis becomes a global health issue, accounting 
annually for an estimated 800000 deaths worldwide.  
Exact incidence rates are difficult to estimate as cirrhosis often remains 
unnoticed until end-stage liver failure has occurred. However, in Belgium, about 
84000 patients were diagnosed with cirrhosis in 2008 and 2009, of whom 4769 
patients died in a Belgian hospital. Although several treatments (Antibiotics, 
healthy diet, abstaining from alcohol etc.) attempt to restrict further disease 
progression and reduce complications, liver transplantation is the only appropriate 
option when the liver ceases to function or complications are no longer 
suppressible.  
But even after liver transplantation, long-term survival of the patient is not 
guaranteed as alcohol relapse or liver rejection may occur. To offset the risk of 
relapse, patients suffering from alcoholic cirrhosis are commonly only eligible for 
a liver transplant after establishing a 6 month period of abstinence from alcohol.  
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Lipids are one of the necessary components which control cellular functions 
and homeostasis. Liver plays an essential role in lipid metabolism, several stages 
of lipid synthesis and transportation.   
The liver plays a key role in the metabolism of plasma lipids and 
lipoproteins. As majority of endogenous cholesterol is synthesized in the hepatic 
microsomes. Synthesis and metabolism of cholesterol is impaired in chronic liver 
disease resulting in a decrease in plasma levels. Severe metabolic impairment in 
cirrhosis can produce a worsening of the serum lipoprotein pattern. High‑ density 
lipoprotein (HDL) cholesterol and its major Apo lipoproteins have been shown to 
be reduced in cirrhosis, as also the serum levels of low‑density lipoprotein (LDL) 
cholesterol. 
         Hence this study aims at studying the lipid profile changes in Cirrhosis, 
thereby reassessing the need for lipid profile in all the patients as a prognostic 
tool. 
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AIMS AND OBJECTIVES 
 
 The study of lipid profile [Total cholesterol (TC), triglycerides (TG) 
high density lipoprotein (HDL), low density lipoprotein (LDL) and very 
low density lipoprotein (VLDL)] changes in cirrhosis of liver. 
 Correlation of lipid changes with various complication of Cirrhosis. 
 To assess the severity of Cirrhosis related to lipid profile changes.  
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2. REVIEW OF LITERATURE 
 
2.1.  HEPATIC ANATOMY 
The liver- Hepar in Greek, is the largest parenchymal organ, weighting 
approximately 1.2 - 1.5 kg even at rest, the liver receives up to 25% of the total 
cardiac output (1), indicating its major role in the metabolism and its necessity for 
survival. Various metabolic and detoxifying functions are carried out by the liver. 
As the main site of glycogenolysis and gluconeogenesis, the liver is involved in 
regulating the blood sugar level. Other metabolic functions include the breakdown 
of proteins and lipids, and the synthesis of cholesterol and triglycerides. 
The most prominent detoxifying function of the liver is the 
biotransformation of lipophilic substances (Medication, nutrition additives, steroid 
hormones etc.) in order to make them more water-soluble and thus to increase the 
possibility of excretion. The liver also produces daily about 500 ml of bile, which 
either drains directly into the duodenum or is temporarily stored in the gallbladder.  
The liver relies on liver cells as well as on three mass transport systems to ensure 
the metabolic work load and the removal of drugs and toxins from the blood. The 
mass transport systems consist of the vascular system, the biliary system and the 
lymphatic system. 
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2.1.1. HEPATIC BLOOD SUPPLY 
Unlike other organs, the liver’s vascular system is composed of two 
supplying blood vessels, the hepatic artery and the portal vein. Both vessels ramify 
at the level of the liver hilum in branches towards the right and left lobe. The 
hepatic artery provides the liver with oxygenated blood, accounting for nearly one 
third of the total blood flow to the liver.  
 
Fig: 1. Blood Supply of Liver 
The remaining blood supply is delivered by the portal vein and contains 
nutrient enriched but partially oxygen depleted blood from the intestines. Venous 
drainage of the liver is assured via the hepatic veins. The hepatic arterial buffer 
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response (HABR) is a mechanism to regulate the hepatic blood supply. Alterations 
in the portal flow are compensated by changes in hepatic arterial flow in order to 
ensure a constant hepatic blood flow. The mechanism depends on the amount of 
adenosine locally washed away by the portal blood flow, resulting in either arterial 
dilation or contraction (2). 
The hepatic biliary tree counts two hepatic bile ducts emerging from the 
liver. Both unite in the live hilum to form the common hepatic duct, which guides 
the bile produced in the liver into the duodenum (1). The liver also produces a 
large amount of lymph, which is mainly produced at a microstructural level (The 
sinusoids). As a consequence, the liver has a deep lymphatic network to ensure the 
drainage of the lymph directionally towards the heart (3). 
2.1.2 FUNCTIONAL ANATOMY 
2.1.2.1 HEPATIC LOBULE 
The liver lobes are on a microstructural level, composed of repetitive 
anatomical units called lobules (4). The lobules resemble the shape of hexagonal 
prisms, which are penetrated by portal tracts at the periphery and central veins in 
the centrum. The different vessel systems are separated by approximately 0.5 mm 
(5). Portal triads contain the terminal intrahepatic ramifications of the portal vein, 
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hepatic artery and bile duct (Respectively portal venule, hepatic arteriole and a bile 
ductule).  
2.1.2.2 HEPATIC ACINUS 
When looking from a metabolic perspective to the microcirculation, one of 
the proposed functional units is the hepatic acinus (6). The acinus is centered on a 
line connecting two terminal portal tracts and is divided in different metabolic 
zones.  
 
Fig: 2. Hepatic Acinus 
The periportal zone I is situated closest to the arriving oxygenated blood 
flow. Therefore, zone I hepatocytes are specialized in oxidative liver functions 
(e.g. gluconeogenesis). The centrilobular zone III, on the other hand, receives 
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blood of inferior quality and thus may suffer most from ischemic injury. Although 
this region is easily subjected to damage, it still provides a significant contribution 
to the detoxification of blood. 
Hepatocytes residing in zone II have functional and morphological 
properties intermediate between cells of zones I and III. Hence, hepatocytes 
contained within zone I survive longer and may form the basis for liver 
regeneration after partial hepatectomy or hepatocellular damage.  
This well-orchestrated regenerative response of the mature functioning cells 
enables the liver to restore lost tissue up to two third of its total mass, while 
simultaneously performing vital functions to maintain the body homeostasis          
(7 & 5). 
2.1.2.3 RHOMBOIDAL ACINUS 
The rhomboidal acinus is located on the line connecting two terminal portal 
triads consisting of a portal venule, hepatic arteriole and bile ductule. Zones I, II, 
and III represent metabolic regions increasingly distant from the blood supply. 
Zone I receives blood with the best quality with regard to oxygen and nutrients. 
The circulatory peripheral zone III suffers most from injury (8). 
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2.1.2.4. SINUSOIDAL CELLS 
The sinusoids are lined by endothelial cells, which contain no basal lamina. 
Plasma constituents gain access to the sub endothelial space of Disse due to 
fenestrae (approximately 0:1μm in diameter) acting as transport pores in the 
continuous endothelial lining. 
 
Fig: 3. Rhomboidal Acinus 
The space of Disse is composed of permeable connective tissue and is 
situated between the hepatocytes and the sinusoids. Fenestrae have a dynamic 
cytoskeleton to preserve and control their size, which can be influenced by various 
factors like alcohol, nicotine, etc. Hence, a graded barrier is formed, keeping 
macromolecules and red blood cells within the vascular space due to their size. 
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White blood cells, however are able to migrate through the endothelial cells into 
the space of Disse and thence to the periportal region where lymph vessels in the 
connective tissue ensure their return into the bloodstream. Moreover, pinocytosis, 
carried out by the endothelial cells, enables the clearance of other vital (macro) 
molecules from the circulation. Sinusoids thus form a vascular bed that functions 
as a biofilter. The extracellular matrix may alter the sinusoidal capacity to sieve the 
passing blood particles as it influences the diameter of the endothelial fenestrae (5). 
2.2  CIRRHOSIS 
  The liver is an organ that can withstand a certain degree of damage, because 
of its remarkable ability to regenerate lost tissue after injury. However, in case of 
cirrhosis, repeated insults or chronic liver disease diffusely damages the liver cells 
in the whole organ, causing inflammatory changes which result in cell necrosis.  
As a reaction to the damaging process, fibrogenesis is activated to cooperate 
in the wound healing process. In addition, hyperplasia of the surviving cells 
eventually occurs leading to the formation of hepatocellular nodules. As injury to 
the liver cells advances, progressive scarring of the liver and distortion of its 
architecture manifests, causing hepatic impairment. Cirrhosis tends to get worse 
over time and may even become life threatening. Despite several attempts, no all-
encompassing definition exists to describe cirrhosis in all its aspects.  
12 
 
The currently most used definition dates back from 1978 (Anthony) and is 
exclusively defined in morphological terms:  
Cirrhosis is a diffuse process characterized by fibrosis and the conversion of 
normal architecture into structurally abnormal (regenerative) nodules (9).  
Two independent characteristics, the connective tissue septa and 
regenerative nodules, account for the main pathophysiologic chronic condition of 
cirrhosis, irrespective of its etiologic starting point. Despite the fact that 
parenchymal necrosis is omitted from the morphological definition, it is generally 
presumed that a large part of the fibrosis synthesis is the result of necrosis. 
Necrosis is therefore an essential feature as it entails not only the premature death 
of cells but also the accompanying environmental reactions to and the 
disappearance of dead cells.  
The term cirrhosis thus implies an alteration of the hepatic circulation and is 
traditionally assumed to be irreversible. In contrast, a recent study indicates that 
cirrhosis regression or even reversal can be achieved after the successful treatment 
of the underlying liver disease coupled with antifibrotic agents. 
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2.2.1. ETIOLOGY 
Cirrhosis is defined as widespread fibrosis and nodule formation. Congenital 
hepatic fibrosis consists of fibrosis without nodules. Partial nodular transformation 
consists of nodules without fibrosis. Cirrhosis is a dynamic and complex process 
which may be evoked by nutritional deficiencies, chemical agents and lack of 
oxygen, viral and bacterial infections and metabolic disturbances. The most 
common diseases that give rise to cirrhosis include chronic hepatitis, fatty liver 
disease and chronic biliary disease (10). Alcoholic liver disease and hepatitis C are 
the predominant causes of cirrhosis in Western countries, whereas the prevalence 
of hepatitis B-induced cirrhosis is vastly increasing in developing countries. Since 
the detection of the hepatitis C virus and non-alcoholic steatohepatitis, cirrhosis of 
which the etiology cannot be diagnosed (Cryptogenic cirrhosis) only rarely occurs 
(11). Often, co-factors including age, sex, obesity, alcohol and genetic factors 
interact with the prevailing cause. Alcohol consumption, for instance, may severely 
increase the likelihood of disease progression in patients with hepatitis B or C (5). 
The following are various causes of Cirrhosis. 
 Viral hepatitis (A, B, C, D, E and G)  
 Alcohol 
 NASH 
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 Metabolic iron overload (HFE  haemochromatosis) 
 Copper overload (Wilson ’s disease) 
 Alpha 1 - antitrypsin deficiency 
 Type IV glycogen storage diseases 
 Galactosaemia 
 Tyrosinaemia 
 Primary biliary cirrhosis 
 Primary sclerosing cholangitis 
 Hepatic venous outflow block (Budd – Chiari syndrome) 
 Heart failure 
 Autoimmune hepatitis 
 Toxins and drugs, e.g. methotrexate and amiodarone 
Many liver diseases have a major initiating factor and a number of               
co - factors contributing to the development of cirrhosis. 
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Fig.4. Co - Factors for Development of Cirrhosis 
Patients with insulin resistance or diabetes mellitus, or who are immune 
suppressed, are at higher risk for developing cirrhosis from several etiologies. Thus 
in many cases there can be a principal factor and interacting co - factors which 
cause a patient to develop cirrhosis. The relative importance of these co -factors 
may vary from patient to patient (5). 
2.2.1.1. CHRONIC HEPATITIS 
Common forms of chronic hepatitis include hepatitis B, hepatitis C and 
autoimmune hepatitis. Pathological features that arise in chronic viral hepatitis 
comprise parenchymal cell necrosis and periportal inflammation. 
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2.2.1.1.1. HEPATITIS C 
The hepatic C virus (HCV) most likely evolves a mechanism to interfere 
with immune signaling pathways and to prohibit antiviral actions. As such, the 
virus enables the evasion of the host innate and adaptive immune response inside 
infected hepatocytes. In addition, cytotoxic activity of natural killer cells towards 
HCV-infected liver cells is down regulated. So once chronicity is established, the 
virus can persevere despite the presence of cytotoxic T lymphocytes (CTL) and, 
moreover, it is believed to be insensitive to antiviral cytokines. However, infected 
and inflamed areas still initiate fibrogenesis through activation of hepatic stellate 
cells with cytokines and other signaling molecules.  Regions around the portal 
tracts are primarily affected, the fibrosis thereafter gradually extends out into the 
lobules towards the central veins (5). 
2.2.1.1.2. HEPATITIS B 
The pathogenesis of hepatic B virus (HBV)-related liver injury is driven by 
complex interactions between the virus and the host immune response. Patients 
affected with chronic hepatitis B do contain antibodies against hepatitis B, 
however, these antibodies are not enough to overpower the infection. The virus 
manages to infiltrate hepatocytes through endocytosis. Its continued reproduction 
inside hepatocytes causes the adaptive immune response, in particular virus 
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specific CTLs, to react in an attempt to purify HBV from affected hepatocytes. The 
killing of infected but viable liver cells contributes to most of the hepatocellular 
necrosis (12 & 5). 
2.2.1.1.3. AUTOIMMUNE HEPATITIS 
Autoimmune hepatitis occurs when the host immune system invades hepatic 
cells. Genetic predisposition or acute liver infection may be underlying reasons. 
The abnormal immune response leads to liver inflammation and cell necrosis. Both 
hepatitis B and autoimmune hepatitis are considered high grade necro 
inflammatory diseases, as opposed to hepatitis C. Therefore, large regions of 
parenchymal extinction are commonly produced by the former (5). 
2.2.1.2. ALCOHOLIC FATTY LIVER DISEASE 
Sustained alcohol abuse favors the development of alcoholic fatty liver 
disease.  Excess alcohol intake leads to an increased oxidative stress via generation 
of reactive oxygen species (ROS). Some of the consequences of increased ROS 
include altered mitochondrial activity, DNA damage, the destruction of membranes 
via lipid peroxidation, and the release of pro inflammatory cytokines. 
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Fig.5. Mechanisms of ALD 
The impaired oxidative capacity of the mitochondria leads to accumulation 
of intracellular lipids, thereby evoking steatosis. The vesicular fatty changes are 
often accompanied by progressive liver inflammation (13). High-ethanol blood 
levels also enhance the oxygen uptake and metabolization by liver cells. The blood 
flow, however, cannot comply with the increased oxygen demand. In addition, 
ethanol induces diminished release of nitric oxide (NO) in the cirrhotic liver. The 
decreased NO levels promote intra hepatic vasoconstriction and portal 
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hypertension. Both oxygen deficiency and reduced perfusion cause a hypoxic state 
in centrilobular regions of the liver lobule.  
 
Fig.6. Pathogenesis of ALD 
Disorders of energy metabolism, ensued from either hypoxia or decreased 
mitochondrial activity, can lead to hepatic injury (5 & 13). Furthermore, chronic 
alcohol consumption increases the absorption of bacterial endotoxins. The 
endotoxins, in turn, sensitize Kupffer cells, causing the exaggerated transcription 
of proinflammatory cytokines (TNF-a, IL-6 and TGF-b).  
The cytokines promote activation of stellate cells and induce 
necroinflammation or apoptosis, leading to collagen synthesis and hepatocyte 
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ballooning (liver cell degeneration due to swelling and enlargement). Sinusoidal 
fibrosis is often associated with alcoholic fatty liver disease, as it predominates in 
the centrilobular zone situated around terminal hepatic vein (13).  
2.2.1.3. NON-ALCOHOLIC FATTY LIVER DISEASE 
Non-alcoholic fatty liver disease is commonly diagnosed in people with 
diabetes and obesity. The relatively benign disease, which is related to metabolic 
syndrome, can progress to inflammation of the liver and concomitant fat 
accumulation (5 & 14).  
2.2.1.4. CHRONIC BILIARY DISEASE 
Chronic biliary diseases are marked by extra- or intra hepatic cholestasis. 
Though prolonged biliary obstruction usually causes the inflammatory destruction 
of bile ducts, metabolic disturbances (Genetic defects and medications) are also 
considered as underlying causes. The progressive damage to the ducts  impairs the 
drainage of bile acids. Biliary products accumulate in the liver and, when leaking 
outwards, damage the normal tissue. A network of fibrotic septa connecting 
enlarged portal triads are often found in biliary cirrhosis. Other cirrhotic features, 
including regenerative nodules and anastomoses, are rarer and less developed (14 
& 10). 
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2.2.2. PATHOGENESIS  
2.2.2.1. FIBROGENESIS 
Fibrogenesis is an innate reparative process that contributes to the natural 
wound healing response in injured tissue. Fibrous connective tissue is produced in 
an attempt to limit and encapsulate the damaged area. However, sustained signals 
associated with chronic or repetitive hepatocellular injury result in excessive 
formation of scar tissue. Persistent accumulation of fibrosis can eventually cause 
the development of cirrhosis (13 & 15).  
The evolution of a normal to fibrotic and subsequent cirrhotic liver is a 
complex process engaging several hepatic cells and mediators to restrict the 
damage. The progression of fibrosis can vary among individuals and depends on 
the cause of hepatic injury. In addition, factors including alcohol consumption, 
male gender and greater age at the time of infection are all associated with ‘rapid 
fibrosers’. Genetic determinants may also contribute to variable progression     
rates (5). 
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Fig. 7. Fibrogenesis of liver 
In the normal liver, strands of type IV (non-fibrillary) collagen are present in 
the space of Disse among other low-density components to provide cellular support 
and molecular signals.  
The low-density connective tissue matrix and fenestrated basement 
membrane thus enable the unhampered exchange of substances between the 
sinusoidal lumen and hepatocytes. After hepatic injury, a vast increase in high-
density fibril-forming collagen (type I and III) deposition is observed along portal 
tracts, in spaces of Disse and in regions of necroinflammatory collapse.  
The growing accumulation of type I collagen, key characteristic of 
fibrogenesis, originates from both reduced degradation and increased synthesis. 
The hepatic stellate cells (HSC) and portal fibroblasts are the main cell types 
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involved in fibrogenesis that synthesize collagen in the liver. Both cell types differ 
in location and physiology, the stellate cells lie within spaces of Disse whereas 
portal fibroblasts reside within the vicinity of portal tracts (5).  
2.2.2.2. HEPATIC STELLATE CELLS 
In the quiescent state, hepatic stellate cells generate primarily type IV 
collagen. During hepatic injury, inflammatory mediators, including both apoptotic 
and necrotic hepatocytes and paracrine stimuli from neighboring cell types 
(Endothelial cells, Kupffer cells, etc.) initiate the stellate cell activation. 
Subsequently, key cytokines are able to further stimulate the activated HSC 
causing the transformation into myofibroblasts.  
The phenotypic switch induces besides collagen synthesis (type I and III) 
also cellular proliferation, loss of retinoid droplets, increased contractility, 
chemotaxis and the production of matrix-degrading enzymes and inflammatory 
signals. The high-density collagen deposition in the space of Disse leads to an 
increased and denser fibril-forming matrix. Sources producing collagenases with 
activity towards type I collagen are less developed as opposed to collagenases of 
the normal basement membrane collagen type IV.   
The increasing scar matrix can therefore not be sufficiently degraded, which 
hinders the transport of solutes and growth factors across the interstitial space. 
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Irregular matrix deposition generally happens in damaged and inflamed areas of 
the parenchyma and imposes detrimental effects on the hepatocytes’ differentiated 
cell function. Sinusoidal vascular resistance is enlarged by the tonic contraction of 
these myofibroblasts (14).   
A recent study also indicates that paracrine signals released by activated 
HSCs may promote progenitor cell expansion, the outcome of which is either 
hepatic regeneration or promotion of hepatocarcinogenesis (16). Once hepatic 
homeostasis has restored, the activated HSCs either revert to quiescent phenotypes 
or are cleared by apoptosis. The cross-linking of collagen and the maturation of the 
hepatic scar, however, remain the determinants of hepatic fibrosis reversibility 
(15). 
2.2.2.2. PORTAL FIBROBLASTS 
Portal fibroblasts are thought to play a pivotal role in cholestatic liver 
diseases and ischemia (15). The cells are triggered by injury to portal tracts, 
resulting in excessive collagen deposition near ducts and ductules. Their rapid 
proliferation may engender biliary fibrosis to run an aggressive course. 
Furthermore, hepatic macrophages show divergent roles as matrix remodeling 
regulators. During fibrotic progression, macrophages promote fibrogenesis, 
whereas during fibrotic regression matrix degradation is accelerated (16). 
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2.2.2.3. REGENERATIVE NODULES 
Cirrhosis is considered as an advanced stage of liver fibrosis, characterized 
by alterations of the lobular structure and the presence of regenerative nodules and 
vascular anastomoses. Several theories have been offered to elucidate the 
regenerative mechanism and the formation of fibrous septa, two critical events 
inherent to cirrhotic progression. Septa or sheetlike structures arise due to various 
causes. In the presence of steatosis, fat droplets merge to form fatty cysts, around 
which micromembranes develop.  
Eventually the fat disappears from the cysts and the connective tissue 
framework condenses into septa. In addition, stress-induced fissures appear 
between areas of irregular distributed fat. Fine connective tissue membranes are 
deposited in these fissures and cumulate into straight septa (10).  
Fibrotic membranes laid down around inflamed portal tracts, however, are 
more important during the septa-forming process, especially in the absence of 
steatosis. These connective tissue membranes radiate from the portal tracts into the 
parenchyma and converge afterwards to become septa. The septa development 
leads to a rearrangement of liver cell plates. Hepatocellular damage also 
contributes substantially to the septa formation, as irregular tissue stresses can 
evoke intralobular and periportal fissures. In these fissures, membranes aggregate 
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into septa. Furthermore, the lobular collapse following (extensive) necrosis causes 
central fields and portal tracts to become approximated and produces post-necrotic 
scar tissue (10).  
 
Fig. 8. Formation of Regenerative Nodules 
The fibrous septa thus alter the lobular architecture and thereby perturb the 
hepatic blood flow. In chronic biliary diseases, fiber strands, and not the typical 
septa, are formed around the ducts. The accumulation of these strands does 
increase the extracellular matrix but without significantly disturbing the lobular 
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architecture. At a further stage, however, and mainly due to sustained 
inflammatory reactions, septa still arise from these fibers strands (10).  
As a response to necrosis and the altered hepatic hemodynamics, regenerative 
processes take place. These lead to thickening and concentrical rearrangement of 
liver cell plates which have been separated from their natural environment due to 
fibrous septa. The plates’ normal thickness of one cell increases to two cells. This 
regenerative effort combined with the localized proliferation of liver cells islands, 
isolated during necrosis, ensure the diffuse formation and progression of benign 
regenerative nodules (17). 
2.2.2.4. PATHWAYS OF STELLATE CELL ACTIVATION 
Stellate cell activation unfolds progressively in sequential stages; this 
paradigm provides a useful framework for defining fibrogenic events after liver 
injury. In particular, the initiation phase, which refers to early events that render 
the quiescent stellate cell responsive to a range of growth factors, remains an 
important focus.  
Rapid induction of "-PDGF receptor, development of a contractile and 
fibrogenic phenotype, as well as modulation of growth factor signaling are the 
cardinal features of this early response.   
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Features of stellate cell activation can be distinguished between those that 
stimulate initiation and those that contribute to perpetuation. Initiation is provoked 
by soluble stimuli that include oxidant stress signals (Reactive oxygen 
intermediates), apoptotic bodies, lipopolysaccharide (LPS), and paracrine stimuli 
from neighboring cell types including hepatic macrophages (Kupffer cells), 
sinusoidal endothelium and hepatocytes. Perpetuation follows, characterized by a 
number of specific phenotypic changes including proliferation, contractility, 
fibrogenesis, altered matrix degradation, chemotaxis and inflammatory signaling.  
Eventually the fat disappears from the cysts and the connective tissue 
framework condenses into septa. In addition, stress-induced fissures appear 
between areas of irregular distributed fat. Fine connective tissue membranes are 
deposited in these fissures and cumulate into straight septa Fibrotic membranes 
laid down around inflamed portal tracts, however, are more important during the 
septa-forming process, especially in the absence of steatosis. 
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Fig. 9. Pathway of hepatic stellate cell activation 
These connective tissue membranes radiate from the portal tracts into the 
parenchyma and converge afterwards to become septa. The septa development 
leads to a rearrangement of liver cell plates.  
Hepatocellular damage also contributes substantially to the septa formation, 
as irregular tissue stresses can evoke intralobular and periportal fissures. In these 
fissures, membranes aggregate into septa. Furthermore, the lobular collapse 
following (Extensive) necrosis causes central fields and portal tracts to become 
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approximated and produces post-necrotic scar tissue. The fibrous septa thus alter 
the lobular architecture and thereby perturb the hepatic blood flow.  
In chronic biliary diseases, fiber strands, and not the typical septa, are 
formed around the ducts. The accumulation of these strands does increase the 
extracellular matrix but without significantly disturbing the lobular architecture. At 
a further stage, however, and mainly due to sustained inflammatory reactions, 
septa still arise from these fibers strands. As a response to necrosis and the altered 
hepatic hemodynamics, regenerative processes take place. These lead to thickening 
and concentrical rearrangement of liver cell plates which have been separated from 
their natural environment due to fibrous septa.  
This regenerative effort combined with the localized proliferation of liver 
cells Islands, isolated during necrosis, ensure the diffuse formation and progression 
of benign regenerative nodules. The growing nodules, in turn, contribute further to 
the septa condensation by compression of the adjacent tissue.  The normal lobular 
architecture is thereby replaced by structurally abnormal nodules.  
In diseases of intrahepatic bile ducts, nodular conversion is usually not 
induced until the liver is extremely fibrotic. These cholestatic diseases  are more 
often characterized by exaggerated proliferation of ductules to provide an 
alternative route for the obstructed bile.  
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2.2.2.5. MORPHOLOGY OF CIRRHOSIS 
Cirrhosis can be subdivided, based on its morphology, into micronodular or 
macronodular forms. Micronodular cirrhosis implies that almost all the 
regenerative nodules are less than 3mm in diameter (9). It most commonly 
originates from diseases in which a hepatotoxic agent or metabolic disorder 
uniformly affects the lobules. For instance, high-dose ethanol exposure causes 
primarily the deposition of connective tissue septa along sinusoids, linking portal 
tracts to central veins. When nearly all portal tracts and central veins are connected 
by septa, the fibrous tissue strongly constrains the enlarging nodules. Micronodules 
barely contain portal tracts or terminal hepatic veins.  
Cirrhotic macronodules, on the other hand, may comprise residual portal 
structures and central veins, which are not bound by septa. Its diameter varies 
notably and ranges from 3mm to several centimeters. Macronodular cirrhosis is 
usually due to viral hepatitis and arises after continued massive collapse of 
cirrhotic parenchyma, promoting accentuated regeneration (10). Although 
regenerative nodules are benign, it is not uncommon that some progress along a 
carcinogenic pathway to become malignant nodules or hepatocellular carcinoma    
(17). 
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2.2.2.6. HEMODYNAMIC ALTERATIONS 
Additional to the complex molecular processes involved in fibrogenesis 
(interacting cells, fibrogenic mediators, etc.) and the formation of regenerative 
nodules, modifications to the angioarchitecture are also considered as a central 
aspect in the pathological pathway to cirrhosis. These changes, including 
sinusoidal remodeling, angiogenesis and the development of intrahepatic shunts, 
increase the intrahepatic vascular resistance leading to various complications. 
Moreover, the degraded sinusoids hamper the metabolic exchange between 
sinusoids and hepatocytes, which may progress to life-threatening liver failure. 
2.2.2.6.1. SINUSOIDAL CAPILLARIZATION 
Sinusoidal capillarization induces microcirculatory distortions in the liver. It 
comprises collagenization of the space of Disse, deposition of basement 
membranes and alterations of fenestrae is accompanied by a loss of hepatocyte 
microvilli.  
The aggregation of fibrous connective tissue, due to fibrogenesis, hampers 
the diffusion of blood solutes across the extravascular space of Disse during the 
metabolic exchange between sinusoids and hepatocytes. Moreover, the excessive 
33 
 
fibrotic tissue in the space of Disse combined with the hepatic stellate cells’ tonic 
contraction, leads to narrowing of sinusoids and hence increases the sinusoidal 
vascular resistance which, in turn, impedes sinusoidal perfusion (5). 
 
Fig. 10. Collagen deposition and sinusoidal constriction in cirrhosis. 
The formation of basement membranes near the endothelium and 
epithelium, acts as an additional barrier to restrict access to the extravascular 
space. In addition, the number and size of fenestrae progressively decreases in 
cirrhotic livers. The fenestrated sinusoids are therefore transformed into continuous 
and more rigid capillaries, which contribute further to the increasing intrahepatic 
vascular resistance and the subsequent development of portal hypertension.   
The limited permeability of the sinusoids deprives the hepatocytes of 
nutrients and the ability to perform vital metabolic functions. Sinusoidal 
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capillarization hence contributes to liver failure, regardless of the metabolic 
capacity of hepatocytes (18, 19 & 20). 
2.2.2.6.2. ANGIOGENESIS AND INTRAHEPATIC SHUNTS 
The anomalies frequently observed in cirrhotic livers, are angiogenesis and 
the presence of intrahepatic shunts. Both vascular abnormalities predominate along 
regions of active inflammation and fibrous septa. In these hypoxic conditions, the 
transcription of the vascular endothelial growth factor (VEGF) is substantially up 
regulated by hepatic stellate cells in order to stimulate angiogenesis. It is  likely that 
the sustained hypoxic state in fibrotic areas thus gives rise to the formation of new 
blood vessels or the reopening of preformed vessels, to countervail the inadequate 
blood supply and to restore the intrahepatic blood circulation (21 & 22).  
In post-necrotic scars or during the septa formation, liver sinusoids get 
entrapped within connective tissue. After parenchymal collapse, portal and central 
field’s approximate and adjacent septa eventually merge to form fibrous bridges 
between portal tracts and central veins. The bridging separates the sinusoids 
entirely from the parenchyma. While some of the trapped sinusoids are obliterated 
due to the fibrous septa, others are transformed into widened porto-hepatic venous 
anastomoses (or internal Eck’s fistulae). Blood, guided into those low hindrance 
pathways, bypasses the liver cells, and is shunted directly into central veins (5). 
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The intrahepatic shunts thus impoverish the surviving parenchyma of nutritive 
blood supply, and thereby contribute to hepatocellular necrosis (10). With the 
collapse of perivenous tissue during necrosis, portal tracts and central fields 
become approximated.  
The accompanying fibrotic processes often obliterate the smaller portal 
veins, while hepatic arteries are less subjected to the compression. As a 
consequence, the HABR compensatory mechanism increases the part of hepatic 
blood coming from the artery (23). Arteriovenous anastomoses, developed in septa 
connecting portal veins and hepatic arteries, partially redistribute the elevated 
arterial pressure to the portal vein and, as such, contribute to portal        
hypertension (10). 
 2.2.2.6.3. CIRRHOTIC ANGIOARCHITECTURE 
The normal lobular angioarchitecture almost completely disappears in a 
cirrhotic liver due to persistent damage to portal fields. While chronic hepatitis 
lacks the presence of regenerative nodules, spatial disarrangements and alterations 
of the angioarchitecture already appear in this earlier stage of the process toward 
cirrhosis. Fibrous bridges, connecting an enlarged portal tract and hepatic vein, 
contain numerous tortuous and intermingled blood vessels. Various portal veins 
run parallel, of which only a few (asterisks) extend outwards into the parenchyma 
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to nourish liver cells. Those rather small veins resemble point-like inflow sources 
and provide the nutrition for liver cells to regenerate. When regenerative nodules 
become completely isolated from their portal blood supply, hepatic arteries are 
assumed to contribute to the maintenance of the nodules (5). Another hypothesis, 
however, suggests that angiogenic pathways are activated within regenerative 
nodules to promote the formation of new blood vessel (10). 
 
Fig. 11. Formation of Cirrhotic Angioarchitecture 
2.2.3. CLIICAL FEATURE COMPLICATIONS 
Based on clinical outcomes, cirrhosis can be described as either 
compensated or decompensated. Decompensation implies the manifestation of 
clinically evident complications resulting from either portal hypertension or liver 
deficiency (jaundice etc.).  
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Fig.12. Complications of Cirrhosis 
Compensated cirrhosis, on the other hand, is non-symptomatic, as the liver is 
able to compensate for the incurred liver damage. However, it can progress 
towards decompensation (24). 
2.2.3.1. PORTAL HYPERTENSION 
All forms of cirrhosis lead to portal hypertension and the primary event is 
obstruction to portal blood flow. Portal venous blood is diverted into collateral 
channels and some bypasses the liver cells and is shunted directly into the hepatic 
venous radicles in the fibrous septa.  
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Fig.13. Formation of Portal Hypertension 
These portohepatic anastomoses develop from pre - existing sinusoids e 
nclosed in the septa. Even larger portohepatic venous anastomoses are found in the 
cirrhotic liver. About one - third of the total blood flow perfusing the cirrhotic liver 
may bypass sinusoids, and hence functioning liver tissue, through these channels.  
The obstruction to portal flow is partially due to nodules which compress 
hepatic venous radicles. This would lead to a postsinusoidal portal hypertension. 
However, in cirrhosis, the wedged hepatic venous (sinusoidal) and main portal 
pressures are virtually identical and the stasis must extend to the portal inflow 
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vessels. Sinusoids probably provide the greatest resistance to flow. Changes in the 
space of Disse, particularly collagenization, result in sinusoidal narrowing and this 
may be particularly important in the alcoholic. Hepatocyte swelling in the 
alcoholic may also reduce sinusoidal flow. 
Portal hypertension may arise in cirrhotic livers as a consequence of the 
increased intrahepatic vascular resistance (regenerative nodules and fibrous tissue) 
coupled with an increased portal blood flow (hyperdynamic circulation). Due to 
the distorted angioarchitecture and abnormal hemodynamics, the blood pressure in 
the portal venous system, normally varying between 5 and 10 mmHg, then exceeds 
a value of 10 mmHg (24 & 25). The hypertension can be linked to most of the 
clinical complications of cirrhosis.  
2.2.3.2.  ASCITES 
Ascites is the accumulation of excessive fluid within the peritoneal cavity. It 
is most frequently encountered in patients with cirrhosis and other forms of severe 
liver disease, although a number of other disorders may lead to either transudative 
or exudative ascites.  
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2.2.2. PATHOGENESIS 
The accumulation of ascitic fluid represents a state of total body water and 
sodium excess, but the event that initiates this imbalance is unclear. Three theories 
have been proposed.  
The “Underfilling” theory suggests that the primary abnormality is 
inappropriate sequestration of fluid within the splanchnic vascular bed due to 
portal hypertension and a consequent decrease in effective circulating blood 
volume. According to this theory, an apparent decrease in intravascular volume 
(underfilling) is sensed by the kidney, which responds by retaining salt and water.  
The “Overflow” theory suggests that the primary abnormality is 
inappropriate renal retention of salt and water in the absence of volume depletion. 
 A third, more attractive theory, the peripheral arterial vasodilatation 
hypothesis, may unify the earlier theories. It accounts for the constellation of 
arterial hypotension and increased cardiac output in association with high levels of 
vasoconstrictor substances that are routinely found in patients with cirrhosis and 
ascites. Again, sodium retention is considered secondary to arterial vascular 
underfilling which is the result of a disproportionate increase of the vascular 
compartment due to arteriolar vasodilation rather than from decreased intravascular 
volume.  
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According to this theory, portal hypertension results in splanchnic arteriolar 
vasodilation, mediated by nitric oxide, and leads to underfilling of the arterial 
vascular space and baroreceptor-mediated stimulation of reninangiotensin, 
sympathetic output, and antidiuretic hormone release. Regardless of the initiating 
event, a number of factors contribute to accumulation of fluid in the abdominal 
cavity. Elevated levels of serum epinephrine and norepinephrine have been well 
documented. Increased central sympathetic outflow is found in patients with 
cirrhosis and ascites but not in those with cirrhosis alone. Increased sympathetic 
output results in diminished natriuresis by activation of the renin-angiotensin 
system and diminished sensitivity to atrial natriuretic peptide.  
Portal hypertension plays an important role in the formation of ascites by 
raising hydrostatic pressure within the splanchnic capillary bed. Hypoalbuminemia 
and reduced plasma oncotic pressure also favor the extravasation of fluid from 
plasma to the peritoneal cavity. Thus ascites is infrequent in patients with cirrhosis 
unless both portal hypertension and hypoalbuminemia are present. Hepatic lymph 
may weep freely from the surface of the cirrhotic liver due to distortion and 
obstruction of hepatic sinusoids and lymphatics and contribute to ascites formation. 
Renal factors also play an important role in perpetuating ascites. Patients 
with ascites fail to excrete a water load in a normal fashion. They have increased 
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renal sodium reabsorption in proximal and distal tubules, the latter largely due to 
increased plasma renin activity and secondary hyperaldosteronism. Insensitivity to 
circulating atrial natriuretic peptide, often present in elevated concentrations in 
patients with cirrhosis and ascites, may be an important contributory factor in 
many patients. Renal vasoconstriction, perhaps resulting from increased serum 
prostaglandin or catecholamine levels, may also contribute to sodium retention. 
Recently a role for endothelin, a potent vasoconstrictor peptide, has been proposed. 
While elevated levels have been reported by some, this has not been observed by 
others (5). 
2.2.3. CLINICAL FEATURES AND DIAGNOSIS 
Usually ascites is first noticed by the patient because of increasing 
abdominal girth. More pronounced accumulation of fluid may cause shortness of 
breath because of elevation of the diaphragm. When peritoneal fluid accumulat ion 
exceeds 500 mL, ascites may be demonstrated on physical examination by the 
presence of shifting dullness, a fluid wave, or bulging flanks. Ultrasound 
examination, preferably with a Doppler study, can detect smaller quantities of 
ascites.  
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2.2.3.1. VARICES (COLLATERAL CIRCULATION) 
 Extensive portal – systemic venous communications develop in order to 
decompress the high – pressure portal venous system. Maintenance of portal 
hypertension after the collateral are formed, is attributed to a resultant increase in 
splanchnic blood flow.  
2.2.3.1.1.  MAJOR SITES OF COLLATERALS 
 Oesophageal and gastric varices (Left gastric vein and short gastric vein 
join with intercostal, diaphragragmatic, oesophageal and azygos veins of 
the caval system). 
 Heamorrhoids (Superior haemorrhoidal vein of the portal system to 
middle and inferior haemorrhoidal veins of the caval system). 
 Caput medusa (Remnants of the umbilical circulation of the foetus 
present in the falciform ligament may form a large paraumbilical vein). 
 Other sites of anastomoses are retroperitoneal vein, lumber vein, omental 
veins and veins over bare area of the liver. 
2.2.3.1.2. VARICEAL BLEEDING  
 Variceal bleeding occurs when portal venous pressure is more than 12 mm 
Hg. Mostly bleeding arises from oesophageal varices within 3 to 5 cm of the 
oesophagogastric junction or from gastric varices. 
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2.2.3.1.3.  FACTORS PREDISPOSING TO BLEEDING  
 Large varices 
 Endoscopic variceal stigma (red spots and red stripes) 
 High portal pressure 
 Liver failure 
 Drugs (NSAIDs) 
 Tence ascites. 
 
 
Fig. 14. Management of Variceal Bleed  
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2.2.4. HEPATIC ENCEPHALOPATHY 
The hyperdynamic circulation is probably caused by an overproduction of 
nitric oxide, a vasodilator molecule, in the extrahepatic blood flow. The NO 
overproduction is promoted by the increased intestinal permeability of bacterial 
endotoxins. Due to the NO molecule, the vascular resistance in the splanchnic and 
systemic circulations substantially decreases, leading to an increased splanchnic 
blood flow (and portal blood flow) and elevated cardiac output.  
 
Fig.15. Mechanisms of Hepatic Encephalopathy 
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In addition, portal hypertension results in the development of portosystemic 
collaterals. These alternative channels bypass the liver and guide a part of the 
increased portal blood flow directly into the systemic venous system without 
purification. Both hepatocellular failure and portosystemic shunting play a pivotal 
role in hepatic encephalopathy (26).  
 
Fig.16. Management of Hepatic Encephalopathy 
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2.2.5. SPONTANEOUS BACTERIAL PERITONITIS 
 It is defined as infected ascetic fluid in the absence of recognizable 
secondary cause of peritonitis. It is associated with an ascetic protein of <1gm/dL. 
Spontaneous Bacterial Peritonitis (SBP) can occur in upto 30% of individuals. 
2.2.5.1. ORGANISMS 
 Coliforms, Streptococci, Camphylobacter; uaually infection is blood – 
borne. Ascitic fluid infection can also be due to staph. Aureus and Enterococcus. 
E. coli infection is more common. 
2.2.5.2. MECHANISM 
 Bacterial translocation from the gut through mesenteric node. Culture are 
more likely to be positive when 10 ml of ascetic fluid is inoculated into two culture 
bottles at the bed side. If more than two organisms are identified in culture, 
secondary bacterial peritonitis due to preformation should be considered. 
2.2.6. HEPATORENAL SYNDROME 
The haemodynamic alteration in kidneys are as a result of decreased effective 
blood volume and increased sympathetic tone. Increased intra – abdominal and 
renal venous pressure and alteration of balance between vasoactive humoral agents 
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such as renin – angiotensin, prostaglandins, theromboxanes, kinins, endotoxins, 
and renal kallikrein may play a role.  
 
 
Fig.17. Hepatorenal Syndrome 
Involvement of endothelin – 1and 3 has been implicated in hepatorenal 
syndrome. Role of nitric oxide has also been suggested as one of the mechanisms. 
The kidneys are anatomically, histologically and functionally normal. 
49 
 
 Following six criterias must be present to confirm diagnosis; 
 Cirrhosis with ascites 
 Serum creatinine > 1.5 mg %. 
 Absence of other causes of renal failure as evidenced by proteinuria > 
500 mg/dL, urine RBC> 50/HPF and abnormal renal USG. 
 No evidence of treatment with nephrotoxic drugs/vasodilators. 
 Absence of shock 
 Absence of sustained improvement of renal function following at least 2 
days of diuretic withdrawal and volume expansion with albumin. 
2.2.7. HEPATOPULMONARY SYNDROME  
Hepatopulmonary syndrome is characterised by  
 Advanced Chronic Liver Disease 
 Arterial Hypoxaemia (Decreased Pao2) 
 Intra – Pulmonary Vasodilatation 
 No Primary Cardio – Pulmonary Disorder (26). 
2.2.8. OTHER COMPLICATIONS  
 Hyponatraemia 
 High Output Cardiac Failure 
 Peripheral Arterial Vasodilatation 
 Central Under filling Collateral Formation 
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 Increased Splanchnic Blood Flow 
2.3. LIPID METABOLISMS  
2.3.1. THE ADIPOSE TISSUE 
Triglycerides comprise around 95% of dietary lipids and can be stored 
within the specialised storage organ adipose tissue, or within other organs, 
principally liver and muscle. Lipids play essential roles in energy storage, vitamin 
absorption, cellular membrane maintenance and cellular signalling.  
The fatty acid content of the body originates either from exogenous dietary 
sources or from endogenous synthesis. Circulating lipoprotein and chylomicron-
bound lipids increase following an intake of lipid containing foodstuffs. 
Lipoprotein lipase breaks down the triacylglycerol (triglyceride) from these 
circulating complexes, releasing non-esterified fatty acids (NEFA) which are taken 
up into adipocytes, where they are esterified into triglyceride and stored.  
The high energy density of triglyceride (9 kcal/g) means that it is a more 
efficient energy store than protein (4 kcal/kg) or carbohydrates (3.75 kcal/kg). 
During a period of energy demand which is greater than exogenous supply, the 
stored triglyceride is hydrolysed by hormone-sensitive lipase and re-mobilised 
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back into the circulation as NEFA. These opposing actions of lipid storage and 
lipolysis are under strict hormonal control.  
The hormones adrenaline, adrenocorticotropic hormone (ACTH) and 
glucagon promote lipolysis, whereas insulin promotes lipid storage and 
esterification. This hormonal profile is ultimately influenced by metabolic need, 
metabolic reserves and stress. 
Traditionally adipose tissue was considered as being merely the major 
storage organ for triglyceride, and little significance was attributed to ectopic lipid 
storage in liver or muscle. This has radically changed over the past decade or so.  
Adipose tissue has emerged as a major endocrine organ, muscle lipids have 
been implicated in insulin resistance and hepatic lipid in altering local and whole-
body metabolic and inflammatory status. 
Adipose tissue secretes over 100 differing factors including adipokines, 
steroid hormones, fatty acids, and prostaglandins. With the exception of 
adiponectin, these factors are all released in greater amounts with increasing 
adipose tissue volume. Adiponectin, a key regulatory factor, promotes insulin 
sensitivity and β-oxidation. 
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About 20% of the total body weight of a normal young adult constituted by 
adipose tissue. There is almost no limit to the extent to which this stroke of adipose 
tissue can be increased. Thus in obese individual weighing 140 Kg more than 50% 
of the body weight is represented by adipose tissue. 
Adipose tissue is found subcutaneously over the entire body in man, with 
some extra deposits in the areas of the buttocks and breasts. There are large 
deposits of adipose tissue in the mesentery, some around the kidneys and the heart. 
In addition to its physiologic role as a stroke of calories, adipose tissue plays a 
structural role for example in cushioning of viscera and as an insulating layer 
reducing the rates of loss of body heat.  
The mature adipose tissue cell (adipocyte) consists of a large structureless 
droplet of lipid surrounded by a very thin rim of cytoplasm (27). For many years 
adipose tissue was considered to be relatively inert tissue. The mass of the adipose 
tissue in sustaining the body during starving is evident even to the casual observer. 
2.3.2. LIPID CHEMISTRY 
A lipid is a fat like substance that may not actually be related to fatty acids 
although occasionally the terms lipids and lipoids are used synonymously. Lipids 
are waxy, greasy, and oily compounds of the body. It is hydrophobic in nature. In 
the body fat serves as an efficient source of energy, except for the brain. Caloric 
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value of fat is 9KCL/gm. Combination of fat and protein (lipoprotein) are 
important cellular constituents. They form important dietary constituents as an 
account of their high calorific value and the fat soluble vitamins and the essential 
fatty acids contained in them (28 & 29). 
2.3.3. CHEMICAL CLASSIFICATION OF PLASMA LIPIDS 
 Simple lipids 
 Fatty acids 
 Steroids 
 Cholesterol 
 Steroid hormones 
 Vitamin D 
 Carotene 
 Vitamin A,E,K 
 Prostaglandins 
 Complex lipids 
 Triglyceride 
 Cholesterol ester 
 Phospholipids 
 Sphingolipids 
 Waxes 
 
2.3.4. FUNCTIONS 
In general lipids are important as; 
 Structure of cell membranes, because lipids are integral part of all cell 
membranes. 
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 As ready source of energy, because lipids supply over half of the energy 
utilized in basal metabolism. 
 A structure of sex hormones. 
 Thermal blanket, because their presence in subcutaneous tissue insulates 
the body against heat loss. 
2.5.5. FATTY ACIDS 
They are carboxylic acids obtained from the hydrolysis of mainly glycerol 
and cholesterol. They contain on even number of carbon atoms and are straight 
chain derivatives. The chain may be saturated (containing no double bonds) or 
unsaturated (containing one or more double bonds). The main saturated fatty acids 
in the plasma are butyric, caproic, palmitic and stearic acid. 
Unsaturated fatty acids are again subdivided into: 
 Monounsaturated (monoethenoid, monoenoic acids). 
 Poly unsaturated (Polyethenoid, polyenoic acids). 
 Eicosinoids: Comprise prostaglandins, leucotriens, prostaglandins and 
 thrombaxane. 
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Many other fatty acids have been detected in the biologic material Normal 
Values: 250-400 mg/dl. Free fatty acids are immediately available energy source 
and provides much of the energy requirements of the body (28 & 29). 
2.3.5. CHOLESTEROL 
It was first described towards the end of 18th century by French chemist De 
Fourerol. It is distributed in all cells of the body but particularly in nervous tissue.  
Cholesterol is the most important compound of those classed as sterols. It is a 
precursor of bile acids, the steroid hormones and Vitamin D. With fatty acids, it 
forms waxes. It is a stable white crystalline substance insoluble in water but readily 
soluble in chloroform, ether, alcohol, and other fat solvents. The sterol is present in 
high amounts in nervous tissue (2%), liver (0.3%), skin (0.3%) and intestine 
(0.2%) and certain endocrine glands (27 & 29). 
The relative high content of the cholesterol in skin may be related to vitamin 
D formation and that in adrenals to steroid hormones synthesis. Much attention 
being directed to cholesterol at present time, not only because of its close 
relationship to other steroids in the body, but also because cholesterol is  involved 
in certain degenerative changes in the arterial well known as atherosclerosis. 
Normal Values: Range from 160-240 mg/dl. 
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2.3.6. TRIGLYCERIDES (TRIACYLGLYCEROLS) 
The triacylglycerols or so called neutral fats, are esters of the alcohol glycerol 
and fatty acids. According to the current standardized, terminology of the 
International Union of Pure and Applied Chemistry (IPAUC) and the International 
Union of Biochemistry (IUB), the monoglycerides, diglycerides and triglycetides 
are to be designated monoacyl, diacyl and triacylglycerols respectively.  
On hydrolysis triglycerides may yield 3 molecules of fatty acid, and 1 
molecule of glycerol when it is boiled with an alkali such as NAOH or KOH. Then 
glycerol and Na and K salt of fatty acids (soap) are formed (27 & 29). Aggregates 
of triglycerides (80%), phospholipids (7%) and cholesterol (9%) are coated with 
lipoproteins to produce particles called chylomicrons. 
Normal values: 40-150 mg%. 
2.3.7. PHOSPHOLIPIDS 
Phospholipids are complex lipids, resembling triglycerides, but containing 
phosphate and a nitrogenous base. The major phospholipids in plasma are lecithin 
and sphingomyelin. The phosphate and nitrogenous base are water-soluble. Lipids 
are carried in the plasma in the form of lipoprotein complexes. These complexes of 
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lipid and protein impart solubility to the otherwise insoluble lipids, and all lipids 
enter and travel through the blood stream as lipid-protein complexes.  
2.3.8. STRUCTURE OF A LIPOPROTEIN PARTICLE 
The lipoproteins are globular particles of high molecular weight that 
transports non-polar lipids through the plasma. Each lipoprotein particle contains a 
hydrophobic core of triglyceride and cholesterol ester, surrounded by a coat 
containing polar phospholipids, free cholesterol and apoproteins  8 that stabilize the 
lipoprotein particle so that it can remain in solution form in the plasma. The 
apoprotein decides the role of a lipoprotein like binding to specific enzyme or onto 
cell membrane, thus directing the lipoprotein to the site of metabolism. 
Schulz (1897) and Machebouf (1929) suspected the role of lipid protein 
complexes in maintaining the lipids in solution in plasma. Application of new 
physical methods for protein separation including electrophoresis and 
centrifugation expedited progress in lipoprotein chemistry. Tiselius et al in 1941 
reported the existence of two lipoprotein classes, seperable by moving boundary 
electrophoresis. These were alpha and beta lipoproteins. After another decade pre 
betalipoprotein was identified by zonal electrophoresis.  
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2.3.9. MAJOR CLASSES OF APOLIPOPROTEINS 
 Apolipoprotein A (A I,A II) 
 Apolipoprotein B(B48,B100) 
 Apolipoprotein C(CII,III,IV) 
 Apolipoprotein E(E2,E3,E4) 
Apoproteins provide structural stability to lipoproteins (30) such as 
solubilizing lipids, activating enzymes, and initiating receptor mediated clearance 
of lipoproteins. 
 
Table. 1. Major Classes of Lipoproteins 
Measurement of apoprotein A levels may predict patients with increased risk 
of coronary artery disease better than HDL levels. Research has shown that 
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apolipoprotein A appears to be an independent risk factor in the development of 
cardiovascular disease.  
There are two major proteins in the apoprotein B family. The smaller one is 
apoprotein B-48 which is the major structural protein of chylomicrons and is  
responsible for the secretion of the same (30). The larger form is apoprotein B-100, 
the major structural protein of VLDL (31) and LDL. It is essential for the secretion 
of VLDL from liver and as a ligand for removal of LDL by LDL receptor. It may 
be elevated in some patients with coronary heart disease and normal cholesterol 
levels. 
Apoprotein C is found in all lipoproteins. They regulate the activity of 
lipoprotien lipase and inhibit removal of chylomicrons and VLDL by liver.  
Apoprotein C2 activates the enzyme. Its absence prevents normal lipolysis and 
causes hypertriglyceridemia. Apoprotein C3 retards catabolism of VLDL and 
chylomicrons (30). 
Apolipoprotein E also is present in VLDL and chylomicrons. They are 
required for normal catabolism of remnants by a specific receptor on the liver that 
recognizes Apoprotein E. There are three forms of apoprotein E1, E2, E3, E4 (30). 
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2.3.10. NORMAL LIPOPROTEIN METABOLISM 
Chylomicrons are formed from dietary fats and cholesterol absorbed in the 
intestine. They are secreted into the lymph, pass through the thoracic duct and 
eventually enter the systemic circulation. As chylomicrons enter capillaries, they 
come into contact with an enzyme, lipoprotein lipase, located on the surface of 
endothelial cells particularly in adipose tissue and muscle. Lipoprotein lipase needs  
insulin for maintenance of adequate tissue levels. The interaction of chylomicrons 
and lipoprotein lipase results in hydrolysis of triglyceride to fatty acids and 
glycerol. 
 
Fig.18. Cholesterol – Carrying Lipoproteines 
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2.3.11. OVERVIEW OF HEPATIC FATTY ACID METABOLISM IN 
HEALTH 
The liver is the key organ in determining the metabolism and distribution of 
fatty acids. It is the source of endogenous synthesis and degrades or interconverts 
exogenous fatty acids. The resultant fatty acids may either be stored in the liver 
itself, or exported to adipose tissue and muscle. Hepatic fatty acid metabolism is 
dynamic with triglyceride turnover occurring every 2 days.  
Circulating fatty acids are either bound to lipoproteins or albumin. 
Lipoprotein-bound lipids, which include chylomicron complexes, are internalised 
into cells following the formation of a specific apolipoprotein-receptor complex. 
Dietary medium-chain triglycerides enter the portal circulation directly, whereas 
longer chain fatty acids enter the vascular circulation complexed with 
chylomicrons via the lymphatic system and the thoracic duct. 
Historically it was believed that in contrast to lipid-lipoprotein complexes, 
the albumin bound NEFAs are internalised into cells via simple and direct 
penetration of the plasma membrane. The recently discovered cluster 
differentiation protein 36 (CD 36) forms a pathway for hepatic fatty acid uptake 
which is upregulated by insulin and experimental models of NAFLD (Ge, Zhou et 
al. 2010; Larter, Chitturi et al. 2010). As a result NEFAs are the key fatty acid 
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source for the liver with an uptake that is directly proportional to its delivery rate 
(Havel, Kane et al. 1970) and potentially increased by insulin resistance and 
NAFLD. The concentration of circulating NEFAs is dependent on their release 
from adipocytes and myocytes. This is regulated by hormone sensitive lipase, 20 
which is stimulated by adrenaline, and inhibited by insulin (Qureshi and Abrams 
2007). 
Insulin also acts to reduce circulating glucose concentrations by promoting 
its tissue uptake. Insulin resistance however results in increased circulating 
concentrations of insulin, and the principal hepatic fatty acid substrates, namely 
glucose and NEFA. As a result insulin resistance promotes hepatic lipogenesis as 
will be further discussed later. Intra-hepatic fatty acids are cytotoxic (Gibbons, 
Wiggins et al. 2004) and so are further metabolised by three potential and separate 
processes: either beta-oxidation, VLDL synthesis or intra-hepatic storage as 
triglycerides. In the presence of high energy demand, intra-hepatic fatty acids 
undergo oxidation to generate energy in the form of ATP. If there is a low energy 
demand then intra-hepatic fatty acids are esterified into triglycerides and either 
stored in the hepatocyte or exported as VLDL. 
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2.3.11.1. OXIDATION 
Within the mitochondria fatty acids in the form of acyl-CoA molecules are 
progressively cleaved by β-oxidation to generate ATP. The process is initiated at 
the carboxyl end and involves the successive disruption of the link between the α-2 
and β-3 carbon atoms (Lavoie and Gauthier 2006). At the end of each cycle the 
chain is reduced by two carbon atoms, and one molecule of FADH2, NADH and 
acetyl CoA is produced. The acetyl-CoA is then further oxidised within the 
mitochondria via the citric acid cycle, while the FADH2 and NADH enter the 
electron-transport chain. The process is repeated until the whole chain is oxidised. 
Microsomal (α and ω) oxidation occurs within the endoplasmic reticulum by 
members of the cytochrome P450 family. They catalyse the oxidation of a variety 
of exogenous and endogenous compounds and play a relatively minor role in fatty 
acid oxidation. 
2.3.11.2. VLDL SYNTHESIS 
The addition of a single glycerol molecule to three fatty acids forms a 
triglyceride. Triglycerides cannot freely cross hepatocyte membranes, and so are 
either stored within the hepatocyte itself, or are coated in lipoproteins, incorporated 
within VLDL, and exported into the systemic circulation. VLDLs are formed 
within the liver and are a complex fusion of lipoproteins (predominantly 21 
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Apolipoprotein B-100), lipids and phospholipids. VLDL secretion facilitates the 
transfer of intra-hepatic fatty acids to peripheral adipose stores (Gibbons, Wiggins 
et al. 2004). 
2.3.11.3. STORAGE WITHIN THE HEPATOCYTES 
The final option for fatty acids is of conversion to triglycerides and storage 
within the hepatic cytosol. Factors that directly promote hepatic triglyceride 
storage are poorly understood.  
Intra-hepatic storage appears to occur when fatty acid production exceeds the 
liver’s oxidation or exportation abilities.  
Apoprotein C II and insulin are activators of this enzyme and apoprotein C III is 
an inhibitor. After lipolysis is complete, a chylomicron remnant is released back 
into the circulation and is cleared rapidly by the liver, by a specific receptor 
mediated interaction which involves recognition of apoprotein E. The major 
component of the newly secreted chylomicrons are apoproteins B 48 and AI. In the 
lymphatics, the chylomicrons acquire apoproteins C and E mainly from HDL 
particles. VLDL is synthesized endogenously by the liver. The core lipid is 
triglyceride, and 20 % is cholesterol. 
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The major apoprotein is apoprotein B 100. But apoprotein C and E are also 
present. Normally after overnight fast, chylomicrons are cleared from the plasma 
and triglyceride circulates as VLDL. The metabolsim of VLDL is similar to 
chylomicrons, VLDL transports triglycerides to tissues to be used as fuel, or to the 
adipose tissue for storage. After interaction with lipoprotein lipase, a VLDL 
remnant is produced which is converted to LDL or removed by the liver via a 
specific receptor interaction involving apoprotein E. 
HDL is important for removal of cholesterol from the peripheral tissues to the 
liver and for metabolism of chylomicrons and VLDL. The liver and intestine 
secrete nascent HDL particles, which take up cholesterol from chylomicrons and 
VLDL to become HDL3.  
After esterification of plasma HDL cholesterol by enzyme LCAT lecithin 
cholesterol acyl transferase, further uptake of cholesterol transforms HDL3 to 
HDL2. HDL2 can transfer cholesterol to VLDL to be taken up by the liver, or 
deliver cholesterol directly to liver after conversion to HDL3 by hepatic 
triglyceride lipase. 
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2.3.11.4. LIPID TRANSPORT 
2.3.11.4.1. THE EXOGENOUS PATHWAY 
The dietary triglycerides and cholesterol are incorporated into large 
lipoprotein complexes called chylomicrons within the intestinal epithelial cells. 
The chylomicrons are secreted into the intestinal lymph and pass into general 
circulation for transport to the capillaries of adipose tissue and skeletal muscle 
where they adhere to the binding sites on capillary walls, while bound to these 
endothelial surfaces the chylomicrons are exposed to the enzyme lipoprotein 
lipase. Also the chylomicrons contain an apoprotein, apoprotein C-11 activates 
lipase liberating free fatty acids (FFA) and monoglycerides. 
Through the endothelial cells there fatty acids enter the underlying 
adipocytes or muscle cells, where they are either reesterified to triglycerides or 
oxidized (27 & 29). The rest of the chylomicron dissociates from the capillary 
endothelium and reenters the circulation.  
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Fig.19. Mechanisms of VLDL 
It will now form a compound relatively poor in triglycerides and enriched in 
cholesteryl esters. Ultimately chylomicron is converted into a chylomicron 
remnant particle which is transported and taken up by the liver, this is mediated by 
binding of apoprotein E to specific receptors called chylomicron remnant 
receptors. The surface bound remnant particles are taken into the cell and 
degraded. The overall result of chylomicron process is to delivery dietary 
triglycerides to adipose tissue and cholesterol to the liver. In the liver some of 
cholesterol gets converted to bile acids, which are excreted into the intestine to acts 
as detergents and facilitates absorption of dietary fat.  
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2.3.11.4.2. THE ENDOGENOUS PATHWAY 
Carbohydrates gets converted to fatty acids in the liver, it also esterifies the 
fatty acids with glycerol to form glycerides and most endogenous cholesterols  
produced in the liver. From the liver VLDL particles are transported to tissue 
capillaries. In peripheral tissues they are removed in the same way as chylomicrons 
(Hydrolysis by the Enzyme Lipoprotein Lipase).  
 
Fig.20. Mechanisms of HDL 
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The remnants generated from the action of lipoprotein lipase on VLDL are 
designated as intermediate density lipoprotein. Through LDL receptors a portion of 
LDL particle is catabolized by the liver the remaining LDL remain in plasma. 
Ultimately transformation of LDL particle to cholesterol rich LDL (28 & 29).  
The function of LDL is to supply cholesterol to a variety of extra hepatic  
parenchymal cells such as adrenal cortical cells, lymphocytes, muscles cells and 
renal cells. These cells have LDL receptors localized on the cell surface. The 
molecule is bound and enters the cells where the cholesterol is used, released and 
become available to the cell for membrane synthesis (29).  
 
Fig.21. Lipoprotein Metabolism 
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This bindings and uptake of LDL suppresses endogenous synthesis. When 
the membranes of parenchymal and Scavenger cells undergo turnover and the cells 
die and removed, unesterified cholesterol is released into plasma where it binds, 
initially to HDL (catalyze by the plasma enzyme LCAT), transferred to VLDL and 
eventually appear in LDL.  
This establishes a cycle by which LDL delivers cholesterol to extra hepatic 
cells and by which cholesterol is returned to LDL from extrahepatic cells via HDL. 
Most of the cholesterol released from extrahepatic tissue is transported to the liver 
for excretion in the bile.  
The liver plays an essential role in lipid metabolism, several stages of lipid 
synthesis and transportation (32, 33 & 34). Alcohol consumption cause fatty liver, 
alcoholic hepatitis and ultimately, alcoholic cirrhosis in some patients                
(35, 36 & 37). 
The liver plays a key role in the metabolism of plasma lipids and 
lipoproteins (38). Most of the endogenous cholesterol is synthesized in the hepatic 
microsomes, synthesis and metabolism of cholesterol is impaired in chronic liver 
disease resulting in a decrease in plasma levels (39).  
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Severe metabolic impairment in cirrhosis can produce a worsening of the 
serum lipoprotein pattern. High‑density lipoprotein (HDL) cholesterol and its 
major apolipoproteins have been shown to be reduced in cirrhosis, as also the 
serum levels of low‑density lipoprotein (LDL) cholesterol (39). 
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III. MATERIALS AND METHODS 
 
 3.1. STUDY DESIGN  
 This study is a single center non randomized prospective study meant to 
study lipid profile changes   in patients with cirrhosis of liver. 
3.2. STUDY PERIOD 
           Consecutive patients of cirrhosis admitted in Thanjavur medical college 
hospital during the period of January 2014 to august 2014 were taken up for the 
study. 
3.3. STUDY CENTRE  
        This study was carried out in department of medicine Thanjavur medical 
college hospital, Thanjavur, Tamil nadu India. All cases were admitted and 
examine in details in the ward & clinical data was recorded in the profoma 
annexed herein. 
3.4. CLINICAL DETAILS 
      Personal   particular like age, sex   details were obtained. Extensive history will 
be taken to rule out various other conditions which can lead to decrease in lipid 
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profile. Detailed past history   were elicited and evidence of hepatic enchalopathy, 
hepatorenal syndrome and other major complication were notedand previous 
hospitalization were noted.  
3.5. INCLUSION CRITERIA 
 Age more than 18 years 
 Known and established cases of Cirrhosis of liver by ultrasound abdomen 
and biochemical studies. 
3.6. EXCLUSION CRITERIA 
 Patients who had used Insulin or other Oral Hypoglycaemic drugs within 
previous 30 days. 
 Patients who had used cholesterol lowering drugs within previous 30 
days. 
 Patients with other disease likely to decrease the lipid levels like Diabetes 
Mellitus, Hypertension, chronic smokers were excluded. 
3.7. CLINICAL EXAMINATION 
  Clinical examination was done in a detailed manner and vital signs were 
recorded and systemic examination was carried out acites, slenomegaly and all 
other important were noted and recorded. 
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3.8. LIST OF INVESTIGATIONS DONE 
 Total Leukocyte Count 
 Differential Leukocyte Count 
 Hemoglobin 
 ESR 
 Fasting Lipid Profile (Total cholesterol, Triglycerides, HDL, LDL) 
 Random Blood Sugar 
 Blood Urea 
 Serum Creatinine 
 LFT 
 PT 
 INR 
 UGI scopy 
 USG abdomen 
3.9. LIPID PROFILE  
 Blood sample was collected in all patients who was in fasting state.  
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DATA AND STATISTICAL ANALYSIS (ANOVA) 
 The patient data was collected prospectively and entered into the profoma 
(Annexure) the data was digitalized in Microsoft excel software and statistical 
analysis it was done SPSS 20 software. The categorical variable have been 
described as proportion and percentage. The continuous variable have been 
expressed as mean and standard Deviation as well as range.  
The effect of various future on lipid profile changes was analyzed by 
unpaired T- test (Difference between mean) for complications. Chi squire test have 
been used to compare the categorical data P-value < 0.05 was considered 
significant in the study.  
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IV. RESULTS AND ANALYSIS 
 
This study was conducted 50 consecutive patients, with cirrhosis of liver got 
admitted in Thanjavur medical college Hospital studied over a period of eight 
month from January 2014 to Augusts 2014.   This study to determine the levels of 
Total cholesterol, HDL, LDL and Triglycerides in cirrhotic patients.  Extensive 
history was taken to rule out various other conditions which can lead to decrease in 
lipid profile.  
Blood routine investigations such as hemoglobin, total leukocyte count, 
differential leukocyte count, ESR, Random blood sugar, Lipid profile and renal 
function tests LFT, PT, INR and UGI scopy will be done in order to rule out 
various other conditions which can lead to alter the lipid profile. The Lipid profile 
of patients LFT, PT, INR and UGI scopy and clinical complication were computed 
and analyzed.  
4.1. AGE DISTRIBUTION 
In our study of 50 patients below 40 were 32% of the total and above 40 
years of age were 68 %. Among this 68 % maximum were in age group of 41 to 50 
years of age which is 36% of total study group. 
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4.2. SEX AND ALCOHOLISM DISTRIBUTION 
All the patients enrolled in our study were males. Among them 94 % were 
alcoholics. 6% were nonalcoholic. 
4.3. LIPID PROFILE IN CIRRHOTIC PATIENTS IN GENERAL 
 Among total of 50 patients of the patients 46% had total cholesterol 
below 140 and 54% of the patients had total cholesterol above   140. 
 Among total of 50 patients 70 patients had HDL below 40 and 30% of 
the patients had above 40. 
 Among total of 50 patients, 48%of the patients had LDL below 80 and 
52% of the patients had above 80. 
 Among total of 50 patients, 64% patients had below 150 and 36% of the 
patients had above 150. 
4.4. CIRRHOTIC PATIENTS WITH ACSITIES OR SPLENOMEGALY 
 Among total of 50 patients, 82 % patients were with ascites and 18 % 
without ascites. 
 Among total of 50 patients, 88% patients were with splenomegaly and 12 
% without splenomegaly. 
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4.5. LIPID PROFILE VARIATION IN CIRRHOTIC PATIENTS WITH 
VARIOUS PRESENTATIONS. 
 LIPID PROFILE IN PATIENTS WITH HISTORY OF HEPATIC 
ENCEPHALOPATHY (Previously Treated and Recovered) 
The difference in mean of total cholesterol, HDL, LDL. TG among 
two groups ie. Patients with history of encephalopathy (44%) and those 
without encephalopathy (54%) were not statistically significant with            
P value > 0.05. 
 LIPID PROFILE IN PATIENTS WITH HISTORY OF HEPATO 
RENAL SYNDROME 
The difference in mean of total cholesterol, HDL, LDL. TG among 
two groups ie patients with history of hepatorenal syndrome (36% of the 
total) and those without hepatorenal syndrome (64%) were statistically 
significant with P value < 0.05. 
  LIPID PROFILE IN PATIENTS WITH LOW AND NORMAL SERUM 
ALBUMIN 
The difference in mean of total cholesterol, HDL, LDL. TG among 
two groups ie patients with low serum albumin (72%) and those with normal 
serum albumin (28%) were statistically significant with P value < 0.05. 
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 LIPID PROFILE IN PATIENTS WITH VARICES AND WITHOUT 
VARICES IN UGI SCOPY. 
The difference in mean of total cholesterol, HDL, LDL. TG among two 
groups ie patients with varices (68%) and those without varices (32%) were not 
statistically significant with P value > 0.05. 
In our study of 50 patients patients below 40 were 32% of the total and 
above 40 years of age were 68 %. Among this 68 % maximum were in age group 
of 41 to 50 years of age which is 36% of total study group. 
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Table. 2: AGE DISTRIBUTION 
 
Fig. 22: AGE DISTRIBUTION 
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Table. 3: SEX DISTRIBUTION 
 
Fig. 23: SEX DISTRIBUTION 
 
All the patients enrolled in our study were males.  Among them 94 % were 
alcoholics. 6% were nonalcoholic. 
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Table. 4: ALCOHOLISM DISTRIBUTION 
 
Fig. 24: ALCOHOLISM DISTRIBUTION 
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Table. 5: DISTRIBUTION OF TOTAL CHOLESTEROL  
 
Fig. 25: DISTRIBUTION OF TOTAL CHOLESTEROL 
 
Among total of 50 patients of the patients 46% had total cholesterol below 
140 and 54% of the patients had total cholesterol above 140.  
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Table. 6: DISTRIBUTION OF HIGH DENSITY LIPOPROTEIN 
 
Fig. 26: DISTRIBUTION OF HIGH DENSITY LIPOPROTEIN 
 
Among total of 50 patients 70 patients had HDL below 40 and 30% of the 
patients had above 40.  
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Table. 7: DISTRIBUTION OF LOW DENSITY LIPOPROTEIN 
 
Fig. 27: DISTRIBUTION OF LOW DENSITY LIPOPROTEIN 
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Table. 8: DISTRIBUTION OF TRIGLYCERIDE 
 
Fig. 28: DISTRIBUTION OF TRIGLYCERIDE 
 
Among total of 50 patients, 64% patients had below 150 and 36% of the 
patients had above 150. 
87 
 
Table. 9: DISTRIBUTION OF COMPLICATION 
 
 
Fig. 29: DISTRIBUTION OF COMPLICATION 
 
88 
 
Table. 10: COMPLICATION CORRELATED TO LIPIDS DISTRIBUTION 
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Fig. 30: COMPLICATION CORRELATED TO LIPIDS DISTRIBUTION 
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Table. 11: EVIDENCE OF HEPATIC ENECEPHALOTHY 
 
Fig. 31: EVIDENCE OF HEPATIC ENECEPHALOTHY 
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Table. 12: EVIDENCE OF HEPATO RENAL SYNDROME 
  
Fig. 32: EVIDENCE OF HEPATO RENAL SYNDROME 
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Table. 13: FEATURES OF ASCITES 
  
Fig. 33: FEATURES OF ASCITES 
 
Among total of 50 patients, 82 % patients were with ascites and 18 % 
without ascites.  
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Table. 14: EVIDENCE OF SPLENOMEGALY 
 
Fig. 34: EVIDENCE OF SPLENOMEGALY 
 
Among total of 50 patients, 88% patients were with splenomegaly and 12 % 
without splenomegaly.  
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Table. 15: DISTRIBUTION OF SERUM ALBUMINE  
 
Fig. 35: DISTRIBUTION OF SERUM ALBUMINE 
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Table. 16:  EVIDENCE OF VARIES IN UGI SCOPY 
 
 
Fig. 36: EVIDENCE OF VARIES IN UGI SCOPY 
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 Table. 17: DISTRIBUTION OF LIPIDS   
 
Fig. 37: DISTRIBUTION OF LIPIDS   
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Table. 18: HRS LIPIDS CORELATION  
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Fig. 38: HRS LIPIDS CORELATION 
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Table. 19: LIPIDS DISTRIBUTION IN HRS 
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Fig. 39: LIPIDS DISTRIBUTION IN HRS 
 
 
The difference in mean of total cholesterol, HDL, LDL. TG among two 
groups ie patients with history of hepatorenal syndrome (36% of the total) and 
those without hepatorenal syndrome (64%) were statistically significant with P 
value < 0.05. 
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Table. 20: SERUM ALBUMINE IN LIPIDS DISTRIBUTION  
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Fig. 40: SERUM ALBUMINE IN LIPIDS DISTRIBUTION     
 
 
 
The difference in mean of total cholesterol, HDL, LDL. TG among two 
groups ie patients with low serum albumin (72%) and those with normal serum 
albumin (28%) were statistically not significant with P value > 0.05. 
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Table. 21: VARIES IN UGI SCOPY OF DISTRIBUTION  
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Fig. 41: VARIES IN UGI SCOPY OF DISTRIBUTION 
 
 
The difference in mean of total cholesterol, HDL, LDL. TG among two 
groups ie patients with varices (68%) and those without varices (32%) were not 
statistically significant with P value > 0.05. 
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DISCUSSION 
 
Lipids are the important components of cellular function and also 
homeostasis. Liver play a very essential role in lipid metabolism and various stages 
of lipid synthesis and transportation. Therefore we expect an abnormal lipid profile 
in those with cirrhosis. There is reduced level of serum cholesterol triglyceride, 
high density lipoprotein and low density lipoprotein in patient with chronic liver 
dysfunction because of reduction of lipoprotein biosynthesis (45). 
In our study 50 cirrhotic patient included among this 36% were 41 to 50 
years of age group others are evenly distributed. In Nigerian medical journal shows 
the same result and international monthly journal in the field of hepatology also the 
same result that alcoholic cirrhosis is involved 41 to 50 years of age. 
In our study group 94% of population gave the history of alcohol 
consumption. Nigerian medical journal January February 2013 shows the similar 
results in that all cases were male, except one. They observed that majority of the 
cases (51%) had consumed alcohol regularly for a period of 5‑10 years, followed 
by 22% cases having consumed alcohol for 10‑15 years (41). 
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We noted that total cholesterol below the normal level in 46% of the patients 
included in our study group. High density lipoprotein were low in 70% of the study 
group, low density lipoprotein was low in 48% and 64% have low triglyceride 
level in our study group. 
Various study gave the similar result in Nigerian medical journal January 
February 2013 shows the median total cholesterol and HDL cholesterol were 
significantly low compared with controls groups and LDL cholesterol low level but 
statistically not significant.  
The international monthly journal in the field of hepatology December 2010 
shows there was a significant decrease in serum triglyceride, total, HDL and LDL 
cholesterol levels also the low level in patient with cirrhosis is inversely related 
with the severity of the cirrhosis (40). 
Journal of the Arab society for medical research 2012 the triglyceride, total, 
HDL and LDL cholesterol is impaired in cirrhotic patient irrespective of the 
incidence of hepatocellular carcinoma in those patients. 
The total and LDL cholesterol, triglyceride level was inversely related to the 
severity of cirrhosis without HCC. In cirrhosis associated with hepato cellular 
carcinoma HDL cholesterol have an inverse correlation to the severity of the 
disease. 
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In our study population 50 patients with cirrhosis 48 patients have various 
complications like acites, splenomagly, hapatic in encephalopathy, hepato renal 
syndrome varices about 98% of the total populations.  
We stratified the data with respect to Total cholesterol, Triglycerides, HDL, 
LDL although we stood the statistical analysis to find that whether theirs any 
significant correlation between the lipids abnormality and complication of 
cirrhosis.  
It failed to show any significant association with lipids profile abnormality 
with various complication of cirrhosis of liver.  
Though our study report shows that cirrhosis is associated with low 
cholesterol levels, we proceeded to correlate the two major complications 
including Hepatorenal syndrome and hepatic encephalopathy. HRS is found to 
have statistically significant correlation with the low lipid levels. But there was no 
association with hepatic encephalopathy. 
 Investigation like serum albumin and varices in UGI scopy result were 
found to be not statistically significant.  
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However the result of the study serve as a baseline for further study in lipid 
profile changes in cirrhosis. Further study in this field warranted. In future it may 
provide valid relation between cirrhosis severity and lipid profile changes.  
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
This study was carried out in 50 patients of cirrhosis and we arrived at the 
following conclusions.  
 46% of patients shows significant reduction in  total cholesterol.  
 Among them 70% of them had High Density Lipoproteins cholesterol 
reduction. 
 The Low Density Lipoproteins was reduced in 48% of the study population. 
 Triglyceride also shows the similar trend in reduction almost 64 % had the 
low level.  
 Various complication of cirrhosis failed to shows any significant association 
with low lipid profile but the hepato renal syndrome shows the significant 
correlation with the low lipids level.     
 In our study there is no correlation between the severity of the cirrhosis of 
liver and low lipids profile changes abnormality.  
 So lipid profile should be used as a routine screening test in cirrhosis.  
 These values help to ascertain the prognosis and severity. 
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                                                   PROFORMA 
Name   :                                                                IP No   : 
Age      :                                                                 D.O.A   : 
Sex      :                                                                  D.O.D  : 
Religion :                                                               Hospital : 
Address :                                                             Occupation : 
I. PRESENTING COMPLAINTS:  
1. Distention of abdomen                                              8. Dyspeptic symptoms      
2. Swelling of lower limbs                                            9. Loss of apetite/weight 
3. Pain abdomen                                                           10. Haemetamesis 
4. Mass per abdomen                                                    11. Bleeding per rectum 
5. Fever                                                                          12. Sleep disturbance 
6. Yellowish discoloration of eyes 
7. Altered sensorium 
II. PASTHISTORY 
a. Similar ailments like presenting symptoms 
b. Previous hospitalization  for reduced output ,altered sensorium. 
c. History of Jaundice 
d. Blood transfusion 
e. Intake of Hepatotoxic drugs 
f. History of Immunization 
g. Past history of any abdominal operations 
h. Other illness 
III. PERSONAL HISTORY 
        a. Diet                                 :          Veg./mixed 
        b. Sleep                               :          Disturbed/undisturbed 
        c. Alcohol consumption      :          Duration 
        d. Bowel and micturition habits 
                                      Regular  : 
              Constipation/Diarrhoea : 
        e. Apetitc                                     : 
 
IV. GENERAL PHYSICAL EXAMINATION 
Built            :     Nourishment :                                               
Scalp hair    :      Weight  :                                                                 
Skin             :      Height           :                                                                   
Conjunctiva :      Sclera              : 
                                                                
Oral cavity   : 
 
Neck             :                  Lymph node enlargement :         Yes / No 
                                        Thyroid enlargement         :          Yes / No 
                                          Parotid enlargement        :             Yes / No 
Upper Limbs   :                 Flapping tremors  
                                          Dupytrens contracture  
                                           Palmar erythema          
                                           Spider Navei                 
Oedema                        :                    Pitting/non pitting : 
Jugular venous pulse    : 
Foetar hepaticus            : 
Anaemia                        : 
Icterus                           : 
Cyanosis                        : 
Clubbing                        : 
Lymph nodes                 : 
Gynaecomastia              : 
Vital signs                     :     Pulse/min : 
                                            Blood pressure in mm Hg : 
                                            Temperature                      : 
                                            Respiratory rate                 : 
V. SYSTEMIC EXAMINATION: 
I. Abdominal Examination: 
a. Inspection 
     Shape :            Scaphoid/uniform distention 
     Umbilicus :     Transverse/vertical eversion 
     Skin over the abdomen : Dry/tense/glistening 
     Dilatation of abdominal wall veins: Around umbilicus/Flanks 
     Movements of all quadrants of abdomen : Normal/Restricted 
    Visible persistalisis : 
     Scars and sinuses : 
     Hernial orifices : 
b. Palpation 
   Edema of the abdominal wall 
    Muscle guarding/rigidity 
    Tenderness 
    Abdominal girth at umbilical level 
    Liver : Palpable : Yes/No 
                 Size : Cms below right costal margin in mid clavicular line 
                 Consistency : Soft/firm/hard 
                 Surface : Smooth/Nodu1ar/Irregu1ar 
                 Border : Sharp/Blunt 
                  Tenderness : Present/Absent 
Spleen :            Palpable : Yes/No 
                         Size : Cms below left costal margin in mid clavicular Line 
                        Consistency : Soft/firm/hard 
                        Tenderness : Present/Absent 
Any other palpable mass : 
Measurements of abdomen: 
Abdominal girth at umbilicus : 
Distance between umbilicus and pubic symphysis : 
Distance between umbilicus and xiphisternum : 
c. Percussion 
Fluid thrill : Present/Absent 
Shifting dullness : Present/Absent 
Liver dullness : cms below right costal margin mid clavicular line 
Splenic dullness : Present/Absent 
d. Ausculitatiion 
Over Liver : Rub/Bruie 
Over spleen : Rub 
Bowel sounds : 
e. External Genatalia : 
2. Cardio Vascular system examination 
3. Respiratory system examination 
4. Central nervous system examination  
IX. INVESTIGATIONS 
1. Routine Haematological examination 
                              Hb gm%  :               
                         Total Count  : 
                Differential count  : 
2. Urine analysis : Sugar  : 
            Albumin : Microscopy : 
           Bile salts/Bile pigments  : 
                            Urobilinogen  : 
3. Random blood sugar in mg/dl  : 
4. Blood urea in mg/dl  : 
5. Serum creatinine in mg/dl : 
6. Liver function tests   : 
                            Serum total Billirubin  : 
                            Serum total proteins  : 
                            Serum Albumin   : 
                                 Serum Globulin     : 
                                Albumin/Globulin ratio : 
                                                 S.G.O.T : 
                                                 S.G.P.T : 
                 Serum Alkaline Phosphotase : 
7. Lipid profile            : 
                                   Tota cholesterol : 
                                               HDL       :   
                                                 LDL      :  
                                      Triglyceride     :                        
                                              VLDL      : 
8.PT &INR                                            : 
      
8.ECG                                                    : 
9.Ultrasound abdomen                           : 
     
TREATMENT                                          : 
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1 4087 38 M + 10 - - + + 192 45 115 156 31 3.00 - 
2 4075 46 M + 20 + - + + 167 39 47 105 21 2.80 - 
3 4372 54 M + 20 - - + + 194 39 117 140 38 2.00 + 
4 5692 56 M + 25 + + + + 170 40 92 190 38 3.50 + 
5 12601 50 M + 30 - - - + 192 45 115 160 32 3.20 - 
6 4396 28 M + 10 - + + + 146 37 90 95 19 3.00 + 
7 7415 48 M + 20 - - + - 142 39 82 105 21 2.80 + 
8 17404 48 M + 25 + - + + 196 39 118 195 39 2.40 - 
9 13789 35 M + 10 - - + + 148 40 82 130 26 3.40 + 
10 17984 35 M + 10 + + + + 138 36 79 75 23 2.20 + 
11 18521 48 M + 15 - - + + 154 42 90 110 22 3.20 + 
12 18138 56 M + 20 - - - - 206 40 120 230 46 3.00 - 
13 28313 32 M + 10 - - + + 158 38 92 140 28 2.80 + 
14 29375 45 M + 15 - - + + 156 40 91 125 25 3.20 + 
15 38672 48 M + 20 + - + + 201 37 132 160 32 3.40 - 
16 4860 45 M + 10 - + + + 98 32 52 70 14 3.20 + 
17 4329 32 M + 12 + + + + 204 42 134 190 38 3.00 + 
18 23006 43 M + 20 + - + + 130 30 68 160 32 2.80 - 
19 30085 58 M + 25 - - + + 194 44 108 220 42 2.60 + 
20 38116 64 M + 30 - - + + 110 31 60 95 19 2.20 + 
21 39314 65 M + 25 + + + + 104 36 50 90 18 2.00 - 
22 34378 62 M - - - - - + 120 36 60 120 24 3.40 - 
23 40213 31 M + 20 - + + + 114 40 52 110 22 3.00 + 
24 41612 40 M + 10 + - + + 116 42 54 80 20 3.20 + 
25 43702 40 M + 10 - - + + 126 34 70 110 22 3.00 + 
26 37893 60 M + 28 - - - + 110 38 55 85 17 2.80 - 
27 38012 55 M + 30 + + + + 124 37 50 135 27 2.20 - 
28 38956 60 M + 25 + + + + 90 25 45 100 20 2.00 + 
29 39103 35 M + 20 + + + + 93 29 48 80 16 1.80 + 
30 39261 47 M + 20 - - + - 134 38 70 130 26 1.80 + 
31 40374 38 M + 20 - - - - 137 35 75 135 27 2.80 + 
32 2227 45 M + 10 + - + + 168 44 94 150 30 2.50 + 
33 3769 50 M + 20 - - + - 172 45 90 185 37 3.20   
34 4544 41 M + 15 - + + + 164 46 86 160 32 2.60 + 
35 14736 54 M + 20 + + - + 104 32 54 90 18 2.00 + 
36 19428 52 M - - - - - + 186 45 102 192 38 3.50 + 
37 25150 50 M + 25 + - - - 184 40 108 180 36 2.20 - 
38 28901 55 M + 30 + + +   98 30 52 80 16 2.90 + 
39 29012 45 M + 20 + - - + 180 48 92 200 40 3.00 + 
40 1692 38 M + 10 - - + + 146 37 90 95 19 3.40 + 
41 1693 45 M + 12 + - + + 184 50 96 190 38 3.60 - 
42 2921 38 M + 18 - - + + 174 44 98 160 32 2.60 - 
43 9290 38 M + - - + + + 192 48 106 190 38 3.00 + 
44 15080 60 M + 28 + + + + 90 35 45 100 20 2.00 + 
45 16208 56 M + 15 + - + + 184 44 101 195 39 2.40 + 
46 17493 32 M + 18 - - + + 102 25 65 60 12 2.80 - 
47 80518 64 M + 28 + + + + 110 31 60 95 19 3.00 + 
48 30911 40 M + 30 - - + + 108 33 54 115 21 3.80 - 
49 37764 45 M + 35 + + + + 105 31 52 110 22 2.20 + 
50 38804 44 M + 10 -   + + 96 32 48 80 16 2.00 + 
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